` REC (Recordati Industria Chimica e Farmaceutica SpA) vs DAX Index Comparison - Alpha Spread

REC
vs
DAX Index

Over the past 12 months, REC has underperformed DAX Index, delivering a return of 1% compared to the DAX Index's 13% growth.

Stocks Performance
REC vs DAX Index

Loading
REC
DAX Index
Add Stock

Performance Gap
REC vs DAX Index

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
REC vs DAX Index

Loading
REC
DAX Index
Add Stock

Competitors Performance
Recordati Industria Chimica e Farmaceutica SpA vs Peers

DAX Index
REC
LLY
JNJ
NOVO B
ROG
Add Stock

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Economic Moat
None
Market Cap
10.4B EUR
Industry
Pharmaceuticals

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
HIDDEN
Show
Back to Top